Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 163960, 6 pages
http://dx.doi.org/10.1155/2015/163960
Clinical Study

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection

1Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung City 807, Taiwan
2Department of Internal Medicine, Kaohsiung Municipal United Hospital, Kaohsiung City 804, Taiwan
3Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
4Department of Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City 807, Taiwan
5Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung City 807, Taiwan
6Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung City 812, Taiwan
7School of Medicine, College of Medicine, E-Da Hospital, I-Shou University, Kaohsiung City 824, Taiwan
8Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital and School of Medicine, Tzu Chi University, Hualien 970, Taiwan
9Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taitung Branch, Taitung City 950, Taiwan
10Department of Internal Medicine, Kaohsiung Municipal Cijin Hospital, Kaohsiung City 812, Taiwan
11Center for Infectious Disease and Cancer Research, Kaohsiung Medical University, Kaohsiung City 807, Taiwan
12Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, National Yang-Ming University, Kaohsiung 813, Taiwan

Received 26 September 2014; Revised 16 February 2015; Accepted 16 February 2015

Academic Editor: Paul M. Tulkens

Copyright © 2015 Guang-Hong Jheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. E. L. McColl, “Clinical practice. Helicobacter pylori infection,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1597–1604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. I. Hsu, D. C. Wu, W. C. Chen et al., “Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 10, pp. 5936–5942, 2014. View at Publisher · View at Google Scholar
  3. C.-H. Kuo, H.-M. Hu, F.-C. Kuo et al., “Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial,” Journal of Antimicrobial Chemotherapy, vol. 63, no. 5, pp. 1017–1024, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Sasaki, N. Ogasawara, K. Utsumi et al., “Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin,” Journal of Clinical Biochemistry and Nutrition, vol. 47, no. 1, pp. 53–58, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Y. Graham and L. Fischbach, “Helicobacter pylori treatment in the era of increasing antibiotic resistance,” Gut, vol. 59, no. 8, pp. 1143–1153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Tursi, W. Elisei, G. Giorgetti, M. Picchio, and G. Brandimarte, “Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study,” Panminerva Medica, vol. 56, no. 1, pp. 57–61, 2014. View at Google Scholar · View at Scopus
  7. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. L. G. Coelho, I. Maguinilk, S. Zaterka, J. M. Parente, M. D. C. F. Passos, and J. P. P. Moraes-Filho, “3rd Brazilian consensus on Helicobacter pylori,” Arquivos de Gastroenterologia, vol. 50, no. 2, pp. 1–17, 2013. View at Google Scholar · View at Scopus
  9. A. S. Essa, J. R. Kramer, D. Y. Graham, and G. Treiber, “Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing ‘concomitant therapy’ versus triple therapy for Helicobacter pylori eradication,” Helicobacter, vol. 14, no. 2, pp. 109–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Okada, K. Oki, T. Shirotani et al., “A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate,” Journal of Gastroenterology, vol. 33, no. 5, pp. 640–645, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Treiber, S. Ammon, E. Schneider, and U. Klotz, “Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication,” Helicobacter, vol. 3, no. 1, pp. 54–58, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. C. H. Kuo, P. I. Hsu, F. C. Kuo et al., “Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line helicobacter pylori therapy: a randomized controlled trial,” Journal of Antimicrobial Chemotherapy, vol. 68, no. 1, pp. 222–228, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. C.-H. Chi, C.-Y. Lin, B.-S. Sheu, H.-B. Yang, A.-H. Huang, and J.-J. Wu, “Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 3, pp. 347–353, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. D.-C. Wu, P.-I. Hsu, H.-H. Tseng et al., “Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies,” Medicine, vol. 90, no. 3, pp. 180–185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Gisbert and X. Calvet, “Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori,” Clinical and Experimental Gastroenterology, vol. 5, no. 1, pp. 23–34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. B. H. Lee, N. Kim, T. J. Hwang et al., “Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea,” Helicobacter, vol. 15, no. 1, pp. 38–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Kadayifçi, A. Uygun, Z. Polat et al., “Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori,” The Turkish Journal of Gastroenterology, vol. 23, no. 1, pp. 8–13, 2012. View at Google Scholar · View at Scopus
  18. J. Y. Moon, G. H. Kim, H. S. You et al., “Levofloxacin, metronidazole, and lansoprazole triple therapy compared to quadruple therapy as a second-line treatment of Helicobacter pylori infection in Korea,” Gut and Liver, vol. 7, no. 4, pp. 406–410, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-W. Chung, J. H. Lee, H.-Y. Jung et al., “Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy,” Helicobacter, vol. 16, no. 4, pp. 289–294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-C. Yang, C.-W. Lu, and C.-J. Lin, “Treatment of Helicobacter pylori infection: current status and future concepts,” World Journal of Gastroenterology, vol. 20, no. 18, pp. 5283–5293, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. V. de Francesco, F. Giorgio, C. Hassan et al., “Worldwide H. pylori antibiotic resistance: a systematic review,” Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 4, pp. 409–414, 2010. View at Google Scholar · View at Scopus
  22. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, “Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days,” Helicobacter, vol. 16, no. 2, pp. 139–145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. D. C. Wu, P. I. Hsu, J. Y. Wu et al., “Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection,” Clinical Gastroenterology and Hepatology, vol. 8, no. 1, pp. 36.e1–41.e1, 2010. View at Publisher · View at Google Scholar
  24. W.-L. Chang, B.-S. Sheu, H.-C. Cheng, Y.-J. Yang, H.-B. Yang, and J.-J. Wu, “Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan,” Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 1230–1235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. H. Katelaris, G. M. Forbes, N. J. Talley, and B. Crotty, “A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study,” Gastroenterology, vol. 123, no. 6, pp. 1763–1769, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Song and T. L. Ang, “Second and third line treatment options for Helicobacter pylori eradication,” World Journal of Gastroenterology, vol. 20, no. 6, pp. 1517–1528, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-H. Kuo, S. S. W. Wang, W.-H. Hsu et al., “Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy,” Helicobacter, vol. 15, no. 4, pp. 265–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. T.-S. Wu, H.-M. Hu, F.-C. Kuo, and C.-H. Kuo, “Eradication of Helicobacter pylori infection,” Kaohsiung Journal of Medical Sciences, vol. 30, no. 4, pp. 167–172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. A. C. Ford, P. Malfertheiner, M. Giguère, J. Santana, M. Khan, and P. Moayyedi, “Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis,” World Journal of Gastroenterology, vol. 14, no. 48, pp. 7361–7370, 2008. View at Publisher · View at Google Scholar · View at Scopus